What is Castle Biosciences's stock-based comp?

Castle Biosciences (CSTL) reported stock-based comp of $9.78M in Q1 2026.

How has Castle Biosciences's stock-based comp changed year-over-year?

Castle Biosciences's stock-based comp decreased by 12.6% year-over-year, from $11.18M to $9.78M.

What is the long-term trend for Castle Biosciences's stock-based comp?

Over 4 years (2021 to 2025), Castle Biosciences's stock-based comp has grown at a 20.5% compound annual growth rate (CAGR), from $21.74M to $45.89M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Castle Biosciences CSTL Stock-Based Comp

Stock-Based Comp at other companies

Labcorp HoldingsLH

$31.7M-3.4%

VeracyteVCYT

$12.76M+16.5%

Personalis, Inc.PSNL

$2.55M+15.1%

NeoGenomicsNEO

$9.64M-10.4%

Fulgent Genetics, Inc.FLGT

$9.89M-6.3%

Cogent Biosciences, Inc.COGT

$16.91M+68.9%

Segments

By segment

See full

Reportable Segment$9.78M-12.6%

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's stock-based comp?: Castle Biosciences (CSTL) reported stock-based comp of $9.78M in Q1 2026.
How has Castle Biosciences's stock-based comp changed year-over-year?: Castle Biosciences's stock-based comp decreased by 12.6% year-over-year, from $11.18M to $9.78M.
What is the long-term trend for Castle Biosciences's stock-based comp?: Over 4 years (2021 to 2025), Castle Biosciences's stock-based comp has grown at a 20.5% compound annual growth rate (CAGR), from $21.74M to $45.89M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.